This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.
The biotech industry is witnessing a revival in the early months of 2024 with a series of IPOs worth around $100 million or more and startup financings. This uptick, along with the recovery of biotech’s flagship stock funds and a surge in dealmaking, has sparked optimism about the industry's health.
The recent success stories include companies like CG Oncology, Kyverna Therapeutics, and ArriVent Biopharma, which not only raised more funds than anticipated but also saw their stock prices increase post-IPO. Biotech venture capital has pulled in approximately $15 billion annually in the last two years.
Invivo Partners, a Barcelona-based venture capital firm, is close to securing a new fund of €100 million ($109 million), with a potential to extend up to €120 million, marking its third fund since inception. The firm has conducted notable acquisitions like Sanifit Therapeutics by Vifor Pharma for €205 million and Versantis by Genfit for about €43 million.
However, the sustainability of this IPO resurgence remains uncertain. Following a brisk period of activity in late January and early February, no new IPO plans have been announced.
Observers are cautiously watching whether this initial burst will translate into sustained growth for the sector or if it represents a temporary spike in a typically volatile market landscape.
The IPO slowdown since late 2021 has had a cascading effect on venture funding for biotech startups, making it more challenging to raise funds at desirable valuations.
The focus on late-stage, de-risked investments raises questions about the financing landscape for early-stage biotech innovators and whether a shift in investor sentiment could broaden the pool of IPO candidates.
This current wave of investment aligns with a broader investor thesis that views biotech as a ripe area for growth, driven by technological advancements and an increasing demand for healthcare innovation.
<script type="application/ld+json">
{
"@context": "https://schema.org",
"@type": "Article",
"mainEntityOfPage": {
"@type": "WebPage",
"@id": "https://www.themoney.game/stories/the-biotech-resurgence"
},
"headline": "The Biotech Resurgence",
"description": "This current wave of biotech investment aligns with a broader investor thesis that views the sector as a ripe area for growth.",
"image": "",
"author": {
"@type": "Organization",
"name": "The Money Game",
"url": "https://www.themoney.game"
},
"publisher": {
"@type": "Organization",
"name": "",
"logo": {
"@type": "ImageObject",
"url": ""
}
},
"datePublished": "2024-03-07"
}
</script>
Actions
Pages
Subscribe for newsletter
Stories
Italian space logistics startup D-Orbit has raised $110 million for their satellite deployment and space operations business. The investment is led by Marubeni Corporation from Japan's industrial sector, with participation from various other investors.
D-Orbit provides last-mile satellite delivery, mission control services, and space waste management. The company's model involves a combination of software and hardware development and caters to both government and commercial space projects.
As a logistics provider for companies in the space industry, the company claims that its operational model saves 40% on costs and 85% on time by grouping multiple customers together and bulk-procuring around launches.
D-Orbit's founders, trained as engineers with expertise in space propulsion, flight dynamics, and aerodynamics, envision expanding their services to connect Mars, the asteroid belt, the moon, and Earth through a logistics network. The company also aims to contribute to the circular economy in space technology by addressing the growing issue of space debris through methods like decommissioning satellites and repurposing satellite parts in orbit.
Story
Finnish biotech startup Enifer has secured a €12 million grant from the European Union’s NextGenerationEU programme to pioneer the world's first commercial-scale PEKILO® mycoprotein technology, converting industrial by-products into a high-quality, sustainable protein source.
The alternative protein market is expected to reach $423 billion by 2033, driven by global environmental and health awareness. Enifer's technology taps into this burgeoning market, offering alternative protein with at least 20 times lower carbon emissions compared to traditional protein sources.
“This plant will be a critical stepping stone to scaling the production of PEKILO® as a truly universal protein source – which we aim to commercialize globally across different applications,” shares Simo Ellilä, CEO and co-founder of Enifer.
Enifer's immediate focus includes completing the factory by the end of 2025, scaling up production in 2026, and anticipating regulatory approval for food-grade mycoprotein by 2024, setting the stage for a wider market launch.
Story
Moonwalk Biosciences, co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, has secured $57 million in funding to advance gene therapy with its epigenetic editing technology.
The gene therapy market, set to surge from $7.18 billion in 2024 to $24.67 billion by 2029, continues to innovate with Moonwalk's non-invasive epigenetic editing. This method, targeting epigenetic modifications over DNA alteration, provides safer, more effective treatments for chronic and aging-related diseases.
“Epigenetics is the software of the genome. While changes to the genome are irreversible, edits to the epigenome can be reprogrammed in different ways. Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible,” said Alex Aravanis, M.D., Ph.D., CEO and Co-Founder, Moonwalk Biosciences.
The next steps include clinical trials to validate the safety and efficacy of its epigenetic editing technique. As this technology advances, it could challenge the industry's belief that traditional gene editing, such as CRISPR-Cas9, is the only path forward for gene therapy.
Moonwalk's approach, utilizing AI for predicting epigenetic targets, leverages the body's natural regulation system, offering a nuanced approach to gene control. This resonates with the trend in biotechnology towards precision and personalization, moving away from one-size-fits-all solutions.
Story
Innovators
Scroll
Open
Close